Policy | July 14, 2024
7th India-Japan medical product regulatory symposium held at New Delhi
Enhanced collaboration under the Memorandum of Cooperation (MoC) between India and Japan in medical product regulations
Enhanced collaboration under the Memorandum of Cooperation (MoC) between India and Japan in medical product regulations
This product will be manufactured at Lupin’s Pithampur facility in India
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
The academy has secured partnerships with 15 esteemed hospitals
Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Dyslipidemia is a critical risk factor for cardiovascular diseases
Subscribe To Our Newsletter & Stay Updated
